recombinant human apolipoprotein M

Recombinant human apolipoprotein M (rhAPOM) is a recombinant version of the human apolipoprotein M (ApoM) protein, a 25 kDa member of the lipocalin protein superfamily. ApoM is primarily expressed in the liver and kidneys and serves as the principal physiological carrier of the bioactive lipid sphingosine-1-phosphate (S1P) in high-density lipoprotein (HDL) particles. Developed by the University of Miami Miller School of Medicine in collaboration with Pfizer's Centers for Therapeutic Innovation, rhAPOM is being investigated as a systemic replacement therapy for glomerular diseases, specifically Alport syndrome. In preclinical models of Alport syndrome (Col4a3 knockout mice), weekly administration of rhAPOM restores renal ApoM levels, reduces triglyceride and lipid droplet accumulation in podocytes by promoting cholesterol efflux, and protects against renal failure, albuminuria, glomerulosclerosis, and tubulointerstitial fibrosis.

Other names

recombinant human ApoMrecombinant human apolipoprotein Mrh-APOMrhAPOM